Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris reported positive Phase 1a data for ATI-052, showing a 45-day half-life and target engagement supporting dosing every three months, confirming its best-in-class potential. The company ended Q1 with $190.8 million in cash, sufficient to fund operations through 2028, following a $59.8 million ATM offering in March.
Key figures
- Revenue
- 1996000
- Revenue Yoy
- 37.2%
- Net loss
- 19800000
- Rd expenses
- 15700000
- Cash position
- 190800000
- Shares outstanding
- 139652849
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.